WHAT’S HAPPENING AT SUNEVA MEDICAL
Recent News
- Suneva Medical Announces Expansion of Bellafill® into South Korea with New Distribution Partnership
- Suneva Medical Launches 30 mL PRP Gel Tubes of Amplifine, Allowing for More Variety and Efficiency in PRP Treatments
- Viveon Health Acquisition Corp. Announces Filing of Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Suneva Medical
Latest on Instagram
So great to spend time with these teams sharing our knowledge and enhancing patient outcomes: @define_maximumwellnessmd and @strellaaesthetics!
#sunevamedical #bellafill #plasmaiq #instalift
Fresh off of our National Sales Meeting Week and celebrating our 1 millionth Bellafill syringe shipped! Starting the week off like…
#sunevamedical #nextgenreg #positivevibes
We’re celebrating a major milestone here at Suneva—as of the close of 2021, we’ve shipped more than a million syringes of Bellafill! Our CEO, Pat Altavilla, put this milestone in perspective of the volume of patients that Bellafill has helped:
“The distribution of Bellafill's millionth syringe is an extraordinary milestone for believers like myself at Suneva, but what's more important to us is the improvement in self-image for the countless patients who have benefited from this product. Bellafill's popularity has grown in recent years, as there are a growing number of patients who are looking for longer-term replacements to shorter-acting fillers, which typically last roughly one to two years.”
With Bellafill being the only FDA-approved 5 year filler, this exciting and energizing milestone has us even more focused on the next million syringes ahead as demand for biostimulators and regenerative aesthetics continues to climb.
Read the full release @ https://bit.ly/1Msyringes
#1millionsyringes #bellafill #sunevamedical
We are excited to announce that the U.S. Food and Drug Administration (FDA) accepted updates to the Plasma IQ™ label, including the removal of the product's eye contraindication. This label update allows Suneva to address treatment around the eye with patients in the United States.
"On the heels of our announcement of the planned merger with Viveon Health Acquisition Corp. to build on our leadership in the regenerative aesthetics sector, we are pleased with the FDA's decision to update the Plasma IQ label," said Pat Altavilla, Chief Executive Officer of Suneva. "We believe Suneva's innovations have always been led by science and I look forward to working with our partner Neauvia to provide access of our Plasma IQ device to a larger patient population looking to improve their aesthetics through a focused energy treatment."
Read the full announcement at https://www.sunevamedical.com/fda-accepts-label-update-for-plasma-iq-the-first-fda-cleared-handheld-plasma-energy-device/
#plasmaiq #fdaclassIIcleared #nextgenregen #sunevamedical #plasmaiqrejuvenation #plasmaiqtightening #plasmaiqtreatment #plasmafibroblast
Upcoming Events
[tribe_events_list limit=”4″ ]
By providing a telephone number and submitting this form you are consenting to be contacted by SMS text message. Message & data rates may apply. You can reply STOP to opt-out of further messaging.
FOR FURTHER INFORMATION
Please use this form to contact Suneva Medical for:
MEDIA INQUIRIES
For press inquiries, please contact at media@sunevamedical.com
MEDICAL AFFAIRS INFORMATION
To request medical information, please complete this electronic form: Medical Information Request
Note: Requests are not valid without practitioner’s e-signature.
PRODUCTS
We strive to ensure a positive experience for patients and practice partners and are continuously committed to providing ongoing support programs and special promotions. Call us at (858) 550-9999.
PRODUCT COMPLAINTS
Please fill out this form to submit a complaint.